Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Cell Free DNA (cfDNA) Testing Market Worth In 2025, And What Is Its Anticipated Value By 2029?
The cell free dna (cfdna) testing market size has witnessed substantial growth in recent years. It is anticipated to increase from $8.74 billion in 2024 to $10.84 billion in 2025, achieving a compound annual growth rate (CAGR) of 24.0%. This historical expansion can be attributed to several factors, including an increased uptake of cfDNA testing in prenatal care, the expanding application of cfDNA analysis, a heightened focus on cfDNA research across various medical domains, and a rise in securing regulatory body approvals.
The cell free dna (cfdna) testing market size is projected to experience substantial expansion in the coming years. By 2029, this market is anticipated to reach $24.34 billion, exhibiting a compound annual growth rate (CAGR) of 22.4%. This growth during the forecast period is driven by several factors, including a move towards personalized medicine, improvements in healthcare infrastructure, an aging population alongside a rise in cancer cases, the growing embrace of precision medicine, heightened awareness and acceptance of liquid biopsy methods, and increased investment and funding for cfDNA research. Key trends expected in the forecast timeframe encompass the integration of liquid biopsy technologies, continuous progress in Next-Generation Sequencing (NGS) technology, the incorporation of AI and machine learning into cfDNA testing, the creation of point-of-care cfDNA diagnostics, and the deployment of cloud-based systems for data management and analysis.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15757&type=smp
Which Factors And Drivers Are Influencing The Cell Free DNA (cfDNA) Testing Market In 2025?
The increasing incidence of cancer is anticipated to fuel the expansion of the cell-free DNA (cfDNA) testing market in the future. Cancer refers to a multifaceted array of illnesses defined by the unchecked proliferation and dissemination of atypical cells within the body. Such cells have the capacity to infiltrate and devastate healthy tissue, potentially causing considerable damage to the body if left untreated. The widespread occurrence of cancer stems from factors like an aging demographic, evolving lifestyle choices, environmental impacts, and improvements in methods for detection and diagnosis. Cell-free DNA testing identifies genetic alterations linked to cancer during its nascent stages, frequently prior to the manifestation of symptoms. This capability facilitates prompt therapeutic intervention, thereby enhancing patient prognoses and survival percentages by pinpointing cancer when it is still in its earliest phases. As an illustration, in February 2024, the World Health Organization (WHO), an intergovernmental body headquartered in Switzerland, projected that new cancer cases would surpass 35 million by 2050, representing a 77% surge compared to the estimated 20 million cases in 2022. Consequently, the escalating incidence of cancer is propelling the expansion of the cell-free DNA (cfDNA) testing market.
How Is The Cell Free DNA (cfDNA) Testing Market Classified Into Different Segments?
The cell free dna (cfdna) testingmarket covered in this report is segmented –
1) By Product: Donor-Derived Cell-Free DNA; Circulating Cell-Free Tumor DNA; Cell-Free Fetal DNA
2) By Platforms: Next Generation Sequencing (NGS); rPCR And Multiplexed PCR; qPCR And dPCR; Other platforms
3) By Application: Oncology; Non-Invasive Prenatal Test (NIPT); Gynecology; Transplantation; Other Applications
Subsegments:
1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring; Graft Rejection Detection
2) By Circulating Cell-Free Tumor DNA: Cancer Detection; Minimal Residual Disease Monitoring; Liquid Biopsy
3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT); Fetal Genetic Disorder Screening
What Trends Are Expected To Drive The Cell Free DNA (cfDNA) Testing Market?
Leading companies within the cell-free DNA (cfDNA) testing market are concentrating on developing innovative technologies, particularly liquid biopsy tests, which provide superior sensitivity, specificity, and efficiency in detecting mutations and genetic alterations linked to cancer. Liquid biopsy tests serve as diagnostic procedures that enable oncologists to examine circulating cell-free DNA originating from tumor cells, thus assisting in the creation of personalized and targeted therapy plans. As an illustration, in May 2023, Laboratory Corporation of America Holdings (Labcorp), a US-based life sciences company, unveiled Labcorp Plasma Focus, a new liquid biopsy test intended for patients diagnosed with advanced or metastatic solid tumors. This test assesses circulating cell-free DNA (cfDNA) released by tumor cells through a standard blood draw, offering a minimally invasive approach and yielding quick results. It contributes to better access to precision oncology by identifying clinically actionable biomarkers in various common cancers, such as non-small cell lung, colorectal, breast, esophageal, gastroesophageal junction, gastric cancers, and melanoma.
Who Are The Top Performing Companies In The Cell Free DNA (cfDNA) Testing Market In Recent Years?
Major companies operating in the cell free DNA (cfDNA) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Bio-Techne Corporation, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Invitae Corporation, Foundation Medicine Inc., Guardant Health Inc., Integrated DNA Technologies Inc., Caris Life Sciences Inc., Twist Bioscience Corporation, Adaptive Biotechnologies Corporation, Biodesix Inc., Biocept Inc., Personal Genome Diagnostics Inc., Agena Bioscience Inc., Menarini Silicon Biosystems Inc., Circulogene Theranostics LLC
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/cell-free-dna-cfdna-testing-global-market-report
Which Global Regions Are Influencing The Competitive Landscape Of The Cell Free DNA (cfDNA) Testing Market?
North America was the largest region in the cell-free DNA (cfDNA) testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (cfDNA) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Cell Free DNA (cfDNA) Testing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=15757&type=smp
Browse Through More Reports Similar to the Global Cell Free DNA (cfDNA) Testing Market 2025, By The Business Research Company
Cellular Health Screening Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report
Carboxymethylcellulose Cmc Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/carboxymethylcellulose-cmc-global-market-report
Autologous Cell Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model